Abstract

Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients

Author(s): Nogales Luis Marcos, Jiménez Labaig Luis, Abarca Lachén Edgar, Gil Melcón María, López-Nieves Marisol

Issue: Sep/Oct 2020 - Volume 24, Number 5

Page(s): 358-364

Download in electronic PDF format for $75
  • Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients Page 1
  • Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients Page 2
  • Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients Page 3
  • Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients Page 4
  • Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients Page 5
  • Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients Page 6
  • Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients Page 7

Abstract

When using ventilators in the management of the coronavirus disease 2019 patient, dense and abundant mucous secretions are formed, obstructing the endotracheal tube and making its aspiration difficult. This situation is worsened if in order to minimize the risk of infection of the medical personnel, the humidifier is disconnected. This circumstance forces the tube to be removed, cleaned, or changed, increasing the workload of the intensive care unit staff. Other therapies tested until now, like mesna, acetylcysteine, or hypertonic saline solution, are valid alternatives, although they have not shown great efficacy for this specific procedure in the past. The sanitary emergency forced the collaboration between a pharmacist and an otorhinolaryngologist to develop the cocamidopropyl betaine surfactant formula, after several tests with different concentrations of the surfactant. The objective of this compounding formula was to resolve a mechanical problem and avoid reintubation due to obstruction of the ventilator tube. The cocamidopropyl betaine surfactant solution 0.075% in saline 0.9% (physiological serum) solution demonstrated to be a well-tolerated formula, using inexpensive materials, was simple to prepare, and was easy to use in clinical practice.

Related Keywords

  • coronavirus disease 2019
  • covid-19
  • ventilator
  • mucous secretions
  • endotracheal tube
  • cleaning
  • cocamidopropyl betaine
  • surfactant
  • formulation
  • compounded sterile preparation
  • hospital pharmacy
  • intensive care unit
  • ICU
  • health emergency

Related Categories

  • FORMULATIONS
  • STERILE PREPARATIONS
  • SUPPORT
  • HOSPITAL PHARMACY
  • INFECTIOUS DISEASE
  • RESPIRATION/LUNG/BREATHING

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Sep/Oct 2020
Pg. 358-364
Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients
Author(s): Nogales Luis Marcos, Jiménez Labaig Luis, Abarca Lachén Edgar, Gil Melcón María, López-Nieves Marisol
Jan/Feb 2023
Pg. 12-21
Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants
Author(s): Riepl Mike
Jul/Aug 2023
Pg. 284-293
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID
Author(s): Riepl Mike, Kaiser Joe
Jul/Aug 2020
Pg. 287-295
Pharmacies on the Frontline: Responding to the COVID-19 Pandemic
Author(s): McElhiney Linda F
Sep/Oct 2023
Pg. 368-380
Compounding for the Treatment of COVID-19 and Long COVID, Part 5: Associated Conditions, Prophylaxis, and Effective Treatment
Author(s): Riepl Mike, Kaiser Joe
Mar/Apr 2023
Pg. 98-107
Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment
Author(s): Riepl Mike
May/Jun 2023
Pg. 192-200
Compounding for the Treatment of COVID-19 and Long COVID, Part 3: The Role of Toll-like Receptors in SARS-CoV-2 Infection and COVID Development
Author(s): Riepl Mike, Kaiser Joe
Jul/Aug 2020
Pg. 268
PreScription: COVID-19 and Compounding Pharmacists
Author(s): Allen Loyd V Jr
Sep/Oct 2020
Pg. 388-395
Basics of Compounding: Excipients Used in Nonsterile Compounding, Part 7: Compounding with Surfactants
Author(s): Allen Loyd V Jr
May/Jun 2022
Pg. 214-217
Basics of Compounding: Vehicle for Drug Administration via Enteral Feeding Tubes
Author(s): Allen Loyd V Jr
Jul/Aug 2003
Pg. 288-291
Basics of Compounding for Raynaud's Disease
Author(s): Glasnapp Andrew
Mar/Apr 2021
Pg. 109-113
Descriptive Report of Individual State Responses to Personal Protective Equipment Shortages for Pharmacy Practice During the Covid-10 Pandemic
Author(s): Roberts Patricia A, Eberwein Samuel M, Youmans Danielle, Amerine Lindsey B
May/Jun 2003
Pg. 188-191
Treating Canine Hepatic Disease
Author(s): Davidson Gigi S
Jul/Aug 2020
Pg. 316
Hydroxychloroquine Sulfate 25 mg/mL in Ora-Plus:Ora-Sweet SF
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 310
Calculations
Author(s): Stockton Shelly J
Jul/Aug 2021
Pg. 268
PreScription: Endemics, Epidemics, and Pandemics
Author(s): Allen Loyd V Jr
May/Jun 2021
Pg. 230-231
Calculations
Author(s): Stockton Shelly J
Jul/Aug 2021
Pg. 296-297
A Permanent Path for Urgent-use Compounding? APC-supported Legislation Would Allow 503As to Fill Gaps in Coverage When 503Bs Cannot
Author(s): Brunner Scott
Sep/Oct 2021
Pg. 386-387
It's Time for a New Philosophy
Author(s): Brunner Scott
Mar/Apr 2022
Pg. 100-109
Allowing Compounding Pharmacies to Address Drug Shortages
Author(s): Broughel James